OncoSec Medical (ONCS) Stock Forecast, Price & News

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for OncoSec Medical in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ONCS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ONCS, but not buy additional shares or sell existing shares.
View ONCS analyst ratings or view top-rated stocks.

OncoSec Medical Incorporated (NASDAQ:ONCS) announced its earnings results on Tuesday, December, 14th. The biotechnology company reported ($5.50) earnings per share (EPS) for the quarter, topping the consensus estimate of ($8.14) by $2.64.

OncoSec Medical's stock reverse split on the morning of Wednesday, November 9th 2022. The 1-22 reverse split was announced on Wednesday, November 9th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, November 9th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

2 employees have rated OncoSec Medical Chief Executive Officer Punit Dhillon on Glassdoor.com. Punit Dhillon has an approval rating of 50% among the company's employees. This puts Punit Dhillon in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other OncoSec Medical investors own include Cytokinetics (CYTK), Inovio Pharmaceuticals (INO), XOMA (XOMA), Anavex Life Sciences (AVXL), Walt Disney (DIS), Idera Pharmaceuticals (IDRA), Sorrento Therapeutics (SRNE), Amarin (AMRN), Dynavax Technologies (DVAX) and Trevena (TRVN).

OncoSec Medical trades on the NASDAQ under the ticker symbol "ONCS."

OncoSec Medical (NASDAQ:ONCS) has a market capitalization of $0.00. The biotechnology company earns $-34,180,000.00 in net income (profit) each year or ($15.2865) on an earnings per share basis.

OncoSec Medical's mailing address is 3565 GENERAL ATOMICS COURT, SAN DIEGO CA, 92121. The official website for the company is www.oncosec.com. The biotechnology company can be reached via phone at (855) 662-6732, via email at investors@oncosec.com, or via fax at 858-430-3832.